Looks at shop purchases before cancer diagnosis in several cancers
Compares past shop purchases of people with and without certain cancers.
Key facts
- Who runs it
- Imperial College London
- Where
- London, United KingdomSee the site
- Trial code
- Registry title
- Cancer Loyalty Card Study 2 (CLOCS-2)
- Status
- Recruiting
- People taking part
- 2,900 people, planned
- Started
- 4 Feb 2026
- Expected to end
- Apr 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Cases & Controls
- Record updated
- 25 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in the United Kingdom who were diagnosed with one of ten cancers in the last 24 months, and adults with no cancer diagnosis. All must hold a Tesco Clubcard or Boots Advantage Card and share its data.
- Age
- Over 18 years
- Sex
- All
- Disease stage
- People with cancer must have been diagnosed in the last 24 months with bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine or vulval cancer. People in the comparison group must have had no cancer diagnosis of any type in the last 6 years, except non-melanoma skin cancer.
Main reasons for not taking part
- Under 18 years old
- Not living in the United Kingdom when giving consent
- No eligible loyalty card (Tesco Clubcard or Boots Advantage Card) in the household
- Not the main registered cardholder, where that cardholder will not join or does not buy for the person
- Cancer diagnosed more than 24 months ago, or any other cancer in the last 6 years, except non-melanoma skin cancer
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Individuals aged >18 years of age
- Individuals must be residing in the United Kingdom at the time of giving informed consent
- Individuals must be registered with an NHS GP Practice
- Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer)
- Individuals must be a primary registered cardholder* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team
- Tesco Clubcard
- Boots Advantage Card
- Provision of written informed consent
- Willing and able to comply with all required study activities; The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder from the same household, wants to take part in the study
Who cannot take part
- they have received an ineligible cancer diagnosis within the last 6 years except where the diagnosis was non-melanoma skin cancer)
- Individuals will not be able to join as a control (Group 2) if:; o they have received any cancer diagnosis in the last six years (except where the diagnosis was non-melanoma skin cancer)
- they have been diagnosed with an eligible cancer type more than 24 months ago (except where the diagnosis was non-melanoma skin cancer)
- Individuals under the age of 18 years
- Non-UK residents, at the time of giving informed consent
- Individuals without an eligible loyalty card, or who have no one in their household who has an eligible loyalty card
- Individuals who are not the primary registered cardholder in their household and where the primary registered loyalty card holder is not willing to join the study, and/or where the primary registered cardholder does not make purchases for or on behalf of the individual
- Individuals will not be able to join as a case if:
This trial is currently available in United Kingdom.
- Imperial College Healthcare NHS TrustLondon, United KingdomContact: Emily PickfordTaking people
About the trial
What the trial wants to find out
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working.
Read full original descriptionShow less
Therefore, early diagnosis is the most important way to improve cancer outcomes.Most of the cancers usually presents with vague and non-alarming symptoms. Most individuals are diagnosed late when the cancer has already spread, and the prognosis is poor. There are over 200 different types of cancer that can cause many different signs and symptoms. Sometimes symptoms affect specific body areas, such as abdomen or skin. But signs can also be more general, and include weight loss, tiredness (fatigue) or unexplained pain. The type of symptoms varies from person to person.
The major reasons for not presenting to the GP with symptoms such as these are "not wanting to waste the GP's time" and normalisation of these symptoms.
The persistence of a symptom, social influence and awareness encourage help-seeking behaviours in primary care. However, few believe their symptom(s) might be a sign of cancer. Consequently, people might choose to self-manage their symptoms by using over-the-counter medication, and to seek advice from other sources, (pharmacists, family, internet), rather than a primary care physician.
RATIONALE FOR CURRENT STUDY
An early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis of cancer can be challenging. Sometimes, the cancer symptoms resemble common illnesses and could resolve with the use of over-the-counter medications and other remedies until they become persistent or debilitating. The present study focuses on ten cancer forms: colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic. Patients diagnosed with the cancers mentioned above often report experiencing vague symptoms (such as abdominal or back pain, indigestion, feeling full etc). They often use over-the-counter medication to manage their symptoms before seeing a doctor.
Information about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or months earlier and encourage people to seek help sooner from their doctors.
The 2 groups in the trial
- Cases
Participants diagnosed with cancer.
Treatment: Cases & Controls
- Controls
Participants not diagnosed with cancer.
Treatment: Cases & Controls
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cancer Loyalty Card Study 2: a Retrospective Observational Case-Control Study
- Plain-language title
- Looks at shop purchases before cancer diagnosis in several cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 25 March 2026